Interface Machine Learning Process Analytical Technology and Process Science For Next Level Process Development.
05th April 2022 | 10:00am EST/ 7:00am PST / 3:00pm GMT / 4:00pm CET | Oliver Steinhof, Senior Scientist Process Analytical Technologies (PAT) at Biogen and Martin Gadsby, Owner, Optimal Industrial Technologies Ltd |WATCH FOR FREE
- The digital evolution as a compelling destination – beyond data-centric knowledge management, opportunities and prerequisites
- Examples and applications for modeling, machine learning and PAT
- Seamless integration of PAT and model life cycle management into a digital plant environment
Presented by Oliver Steinhof, Senior Scientist Process Analytical Technologies (PAT) at Biogen
Supporting the Digital Development and Analytics team at Biogen since 2017 with a focus on PAT implementation and commercialization. Focus over the last 4 years was the startup of Biogen’s Next Generation Manufacturing facility at Solothurn Switzerland. Since 2015 at Lonza Visp, Switzerland, leading the PAT laboratory and providing PAT consulting and solutions to the global Lonza network, including small molecule API manufacture and chemicals. Since 2009 several roles at Shell Global Solutions in Hamburg Germany around lubricants R&D, including management of the analytical services team, global technical support manager, internal consultant, quality auditor and project leader for R&D projects. Chemist by training, spending time at the Universities of Braunschweig Germany, Salt Lake City Utah and Tuscaloosa Alabama. PhD in industrial chemistry sponsored by BASF SE with a focus on on-line NMR spectroscopy and reaction engineering of complex polycondensations.
Followed by Martin Gadsby, Owner, Optimal Industrial Technologies Ltd
Martin graduated from the University of Bath in the late 1970’s, and after working through a few positions in industry, he became the new European R&D Process and Process Automation Group Leader for Kraft Foods. After a few years at Kraft, Martin decided to set up a process automation business with a colleague, Dave Richards, and Optimal was born.
Optimal Industrial Automation was formed over 33 years ago, with Martin now being the main owner and CEO. Optimal Industrial Technologies was formed more recently as the products division and is the market leader in the field of Process Analytical Technology (PAT) with its PAT Knowledge Management product – synTQ. Martin is intimately involved with progressing the evolution of synTQ and advising the Optimal development team on what he believes to be the optimum development direction. Over the last few years, he has taken on the overall responsibility not only for the company but also for the sales and marketing of synTQ whilst remaining very active in ensuring that the development of synTQ continues unabated. On the personal front, Martin is a bit of a ‘petrol head’ and enjoys flying aerobatics and racing cars
Sponsored by Optimal Industrial Technologies Ltd
Within the Optimal group we have more than 30 years experience in the automation and optimisation of control and data management systems for the pharmaceutical, biotech and life science industries with significant experiences in both batch and continuous processing. The demands being placed on manufacturers in relation to getting products to market sooner, minimising development and production costs together with increasing product quality and business sustainability are ever increasing; hence, the company’s primary aim is to deliver measurable improvements in all these target areas and has, though the years, developed many innovative solutions and approaches.
In addition to practical automation and system integration expertise, Optimal Industrial Technologies has also developed the world-leading PAT Knowledge Management software platform – synTQ® which is used by over 60% of the world’s leading pharmaceutical and biotech companies. It has been a proven enabler of QbD via PAT by significantly increasing productivity and quality whilst reducing time to market, waste plus time to manufacture for batch and continuous processes. It is being applied from the laboratory through to full GMP manufacture in small and large molecule drug substance and drug product processes and has assisted in cutting weeks from manufacturing times and in some cases, tripling production capability.